
Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Your AI-Trained Oncology Knowledge Connection!


Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Manish Kohli, MD, discusses the challenges of molecular classification in prostate cancer.

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses ongoing research with correlative sciences in prostate cancer.

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

Published: May 18th 2020 | Updated:

Published: September 4th 2019 | Updated:

Published: September 11th 2019 | Updated:

Published: September 25th 2019 | Updated:

Published: January 25th 2020 | Updated:

Published: May 19th 2020 | Updated: